1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • May 2014
  • 45 pages
  • GlobalData
Report ID: 2166747

Summary

Table of Contents

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Summary

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly’s Cymbalta, and Otsuka/BMS’s Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda’s Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

Seroquel XR (quetiapine) (extended-release tablets) is an atypical antipsychotic that is indicated as an adjunctive treatment for MDD in the US, 5EU, and Australia. AstraZeneca initially developed the Seroquel immediate release formulation for the treatment of schizophrenia and bipolar disorder, but has not gained regulatory approvals for MDD with Seroquel. With the development of Seroquel XR, AstraZeneca expanded the label of this product for the treatment of MDD as an adjunctive therapy, initially in 2009 in the US and Australia, followed by an approval in 2010 in the 5EU.

Scope

- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Seroquel XR including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Seroquel XR for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Seroquel XR performance
- Obtain sales forecast for Seroquel XR from 2013-2023 in the top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: Alzheimer’s Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety ...

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017

  • $ 3995
  • Industry report
  • August 2017
  • by GBI Research

Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 Summary Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity ...

Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • April 2017
  • by GlobalData

Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Bipolar Disorder (Manic Depression) Global Clinical Trials Review, H1, 2017" ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.